Stock VSTM VERASTEM, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Verastem, Inc.

Equities

VSTM

US92337C2035

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
9.38 USD +1.79% Intraday chart for Verastem, Inc. -4.67% +15.23%
Apr. 18 Verastem Names John Hayslip as Chief Medical Officer MT
Apr. 18 Verastem Oncology Announces Executive Changes CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Verastem Names John Hayslip as Chief Medical Officer
MT
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
BU
Verastem Oncology Announces Executive Changes
CI
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
BU
Verastem, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Verastem: Q4 Earnings Snapshot
AQ
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
BU
Verastem, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
BU
Verastem Oncology's Ovarian Cancer Drug Gets FDA Orphan Drug Designation
DJ
Verastem Gets Orphan Drug Designation From US FDA for Avutometinib to Treat Type of Ovarian Cancer
MT
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
BU
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
BU
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
BU
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers
CI
Sector Update: Health Care Stocks Mixed Premarket Friday
MT
Sector Update: Health Care
MT
Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VSTM Stock
  4. News Verastem, Inc.